CN110755434A - 化合物palosuran防治骨骼肌萎缩等疾病的用途 - Google Patents
化合物palosuran防治骨骼肌萎缩等疾病的用途 Download PDFInfo
- Publication number
- CN110755434A CN110755434A CN201810844111.9A CN201810844111A CN110755434A CN 110755434 A CN110755434 A CN 110755434A CN 201810844111 A CN201810844111 A CN 201810844111A CN 110755434 A CN110755434 A CN 110755434A
- Authority
- CN
- China
- Prior art keywords
- skeletal muscle
- compound
- myopathy
- palosuran
- muscle atrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810844111.9A CN110755434B (zh) | 2018-07-27 | 2018-07-27 | 化合物palosuran防治骨骼肌萎缩等疾病的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810844111.9A CN110755434B (zh) | 2018-07-27 | 2018-07-27 | 化合物palosuran防治骨骼肌萎缩等疾病的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110755434A true CN110755434A (zh) | 2020-02-07 |
CN110755434B CN110755434B (zh) | 2022-03-15 |
Family
ID=69327009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810844111.9A Active CN110755434B (zh) | 2018-07-27 | 2018-07-27 | 化合物palosuran防治骨骼肌萎缩等疾病的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110755434B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116139140A (zh) * | 2021-11-19 | 2023-05-23 | 中国医学科学院药物研究所 | 一种化合物在治疗糖皮质激素不良反应中的用途 |
CN117482099A (zh) * | 2024-01-03 | 2024-02-02 | 中日友好医院(中日友好临床医学研究所) | 木通皂苷d在制备抗骨骼肌萎缩、肌病药物中的应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1494542A (zh) * | 2001-03-27 | 2004-05-05 | ������˹ҩƷ��˾ | 作为尾加压素ii受体拮抗剂的1,2,3,4-四氢异喹啉的衍生物 |
CN1617885A (zh) * | 2002-01-16 | 2005-05-18 | 宝洁公司 | 促肾上腺皮质激素释放因子2受体激动剂 |
CN101039930A (zh) * | 2004-10-12 | 2007-09-19 | 埃科特莱茵药品有限公司 | 作为结晶硫酸盐的1-[2-(4-甲苯基-4-羟基-哌啶-1-基)-乙基]-3-(2-甲基-喹啉-4-基)-脲 |
CN101217965A (zh) * | 2005-07-07 | 2008-07-09 | 学校法人浦项工科大学校 | 葡萄糖吸收调节剂和用于治疗糖尿病或糖尿病并发症的方法 |
CN101522197A (zh) * | 2006-07-31 | 2009-09-02 | 詹森药业有限公司 | 尾加压素ⅱ受体拮抗剂 |
WO2013068701A1 (fr) * | 2011-11-10 | 2013-05-16 | Universite De Rouen | Urotensine ii pour son utilisation dans le traitement et/ou la prévention de pathologies impliquant la motilité gastrique |
CN104557618A (zh) * | 2013-10-15 | 2015-04-29 | 南京理工大学 | 一种合成n,n’-二烷基脲的方法 |
CN110038114A (zh) * | 2018-01-15 | 2019-07-23 | 中国医学科学院药物研究所 | 一种多肽在制备预防或治疗代谢综合征药物中的用途 |
-
2018
- 2018-07-27 CN CN201810844111.9A patent/CN110755434B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1494542A (zh) * | 2001-03-27 | 2004-05-05 | ������˹ҩƷ��˾ | 作为尾加压素ii受体拮抗剂的1,2,3,4-四氢异喹啉的衍生物 |
CN1617885A (zh) * | 2002-01-16 | 2005-05-18 | 宝洁公司 | 促肾上腺皮质激素释放因子2受体激动剂 |
US7462597B2 (en) * | 2002-01-16 | 2008-12-09 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
CN101039930A (zh) * | 2004-10-12 | 2007-09-19 | 埃科特莱茵药品有限公司 | 作为结晶硫酸盐的1-[2-(4-甲苯基-4-羟基-哌啶-1-基)-乙基]-3-(2-甲基-喹啉-4-基)-脲 |
CN101217965A (zh) * | 2005-07-07 | 2008-07-09 | 学校法人浦项工科大学校 | 葡萄糖吸收调节剂和用于治疗糖尿病或糖尿病并发症的方法 |
CN101522197A (zh) * | 2006-07-31 | 2009-09-02 | 詹森药业有限公司 | 尾加压素ⅱ受体拮抗剂 |
WO2013068701A1 (fr) * | 2011-11-10 | 2013-05-16 | Universite De Rouen | Urotensine ii pour son utilisation dans le traitement et/ou la prévention de pathologies impliquant la motilité gastrique |
CN104557618A (zh) * | 2013-10-15 | 2015-04-29 | 南京理工大学 | 一种合成n,n’-二烷基脲的方法 |
CN110038114A (zh) * | 2018-01-15 | 2019-07-23 | 中国医学科学院药物研究所 | 一种多肽在制备预防或治疗代谢综合征药物中的用途 |
Non-Patent Citations (4)
Title |
---|
YAVUZ PEHLIVAN 等: "Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension", 《INFLAMMATION》 * |
梁眉黛 等: "2型糖尿病诱导骨骼肌萎缩机制及常用降糖药影响研究进展", 《药学学报》 * |
王红霞 等: "尾加压素Ⅱ及其受体在2型糖尿病骨骼肌组织中高表达的影响因素", 《第七届海峡两岸心血管科学研讨会论文集》 * |
王继 等: "2 型糖尿病与肌萎缩研究进展", 《中国运动医学杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116139140A (zh) * | 2021-11-19 | 2023-05-23 | 中国医学科学院药物研究所 | 一种化合物在治疗糖皮质激素不良反应中的用途 |
CN117482099A (zh) * | 2024-01-03 | 2024-02-02 | 中日友好医院(中日友好临床医学研究所) | 木通皂苷d在制备抗骨骼肌萎缩、肌病药物中的应用 |
CN117482099B (zh) * | 2024-01-03 | 2024-04-09 | 中日友好医院(中日友好临床医学研究所) | 木通皂苷d在制备抗骨骼肌萎缩、肌病药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN110755434B (zh) | 2022-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101740893B1 (ko) | Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물 | |
HU218920B (hu) | Duloxetin alkalmazása inkontinencia kezelésére alkalmas gyógyszerkészítmények előállítására | |
CN110755434B (zh) | 化合物palosuran防治骨骼肌萎缩等疾病的用途 | |
US20080249168A1 (en) | Pharmaceutical composition for gout | |
EP2932972B1 (en) | New application of catalpol | |
CN112603923A (zh) | 连翘苷在制备预防或/和治疗二型糖尿病药物中的应用 | |
CN110038114B (zh) | 一种多肽在制备预防或治疗代谢综合征药物中的用途 | |
CN103813792A (zh) | 用于治疗膀胱过度活动症的索利那新和唾液刺激剂的组合 | |
KR101671008B1 (ko) | TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 식욕억제용 약학적 조성물 | |
US10328051B2 (en) | Proline or proline derivatives for the treatment of dementia | |
CN104547289B (zh) | 一种具有治疗顺铂引起肾损伤作用的中药组合物 | |
CN113116934B (zh) | 五谷虫用于治疗老年痴呆的用途 | |
CN110636847B (zh) | 用于预防及治疗肌肉疾病的组合物 | |
CN110227083A (zh) | 一种含氯化钆和双胍类降糖药的药物组合物及其用途 | |
KR102246627B1 (ko) | Hmba를 포함하는 비만 또는 당뇨의 예방 또는 치료용 조성물 | |
US20200163907A1 (en) | Uses of hydroxyanigorufone | |
KR102427769B1 (ko) | 다발성 경화증 예방 또는 치료용 조성물 | |
CN115624543B (zh) | 治疗偏头痛的药物、药物组合物、其制备方法和制药用途 | |
WO2022061962A1 (zh) | 一种l型氨基酸转运蛋白抑制剂或拮抗剂有效干预糖尿病的方法 | |
WO2007081061A1 (ja) | 神経因性疼痛治療剤 | |
CN114073706A (zh) | 丹参酮iia磺酸钠在制备药物中的应用 | |
CN116139140A (zh) | 一种化合物在治疗糖皮质激素不良反应中的用途 | |
CN116983305A (zh) | 格拉司琼在制备防治代谢综合征药物中的应用 | |
CN116036106A (zh) | 一种治疗淋巴水肿的药物运用 | |
CN117017961A (zh) | 一种莱菔素及其组合物在制备抗疲劳产品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Du Guanhua Inventor after: Yang Xiuying Inventor after: Chen Xi Inventor after: Qiang Guifen Inventor after: Yin Lin Inventor after: Jia Weihua Inventor after: Wang Nuoqi Inventor after: Zhang Li Inventor after: Hou Biyu Inventor before: Du Guanhua Inventor before: Yang Xiuying Inventor before: Chen Xi Inventor before: Qiang Guifen Inventor before: Yin Lin Inventor before: Jia Weihua Inventor before: Wang Nuoqi Inventor before: Zhang Li Inventor before: Hou Biyu |
|
GR01 | Patent grant | ||
GR01 | Patent grant |